Australia markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9050-0.1600 (-7.75%)
At close: 04:00PM EDT
1.9200 +0.01 (+0.79%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 247.29M
Enterprise value 283.55M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.21
Price/book (mrq)11.02
Enterprise value/revenue 2.88
Enterprise value/EBITDA -1.38

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-65.52%
S&P500 52-week change 3-13.21%
52-week high 36.3800
52-week low 31.8000
50-day moving average 32.5804
200-day moving average 33.2284

Share statistics

Avg vol (3-month) 31.76M
Avg vol (10-day) 31.84M
Shares outstanding 5118.89M
Implied shares outstanding 6N/A
Float 884.28M
% held by insiders 10.32%
% held by institutions 1102.74%
Shares short (27 Feb 2023) 423.27M
Short ratio (27 Feb 2023) 413.75
Short % of float (27 Feb 2023) 424.81%
Short % of shares outstanding (27 Feb 2023) 419.57%
Shares short (prior month 30 Jan 2023) 426.79M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022

Profitability

Profit margin -169.05%
Operating margin (ttm)-162.21%

Management effectiveness

Return on assets (ttm)-39.22%
Return on equity (ttm)-399.43%

Income statement

Revenue (ttm)107.67M
Revenue per share (ttm)0.99
Quarterly revenue growth (yoy)45.40%
Gross profit (ttm)N/A
EBITDA -171.86M
Net income avi to common (ttm)-182.02M
Diluted EPS (ttm)-1.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)84.85M
Total cash per share (mrq)0.73
Total debt (mrq)157.48M
Total debt/equity (mrq)1,160.31
Current ratio (mrq)2.49
Book value per share (mrq)0.12

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A